Inhibiting the programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) pathway is a commonly used cancer immunotherapy strategy, but it suffers from drawbacks such as low stability and difficulty in modification of relevant antibodies. The gene discussed is CD274; the disease is cancer.